Early Feasibility Analysis with Applied BioMath Assess™ for checkpoint inhibitors: Is target engagement the whole story?


Target engagement is not always a direct indicator of the degree of checkpoint inhibition, an important consideration for checkpoint inhibitor dose projections. Here we show how the special structure of the Applied BioMath Assess Membrane Ligand Competitor model in Applied BioMath Assess is well-suited for modeling checkpoint inhibitors and explaining this phenomenon with a focus on two immune checkpoint inhibitors, atezolizumab and magrolimab. 


Download the Poster